Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 49

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 49
---
 the notice required under the Sidhu Agreement, $140,760 as compensation in connection with the CEO Transition and $278,346 as a severance payment. In addition, the Settlement Agreement provided for accelerated or continued vesting of then-unvested and outstanding stock options held by Dr. Sidhu with respect to a total of 1,950,000 Class A ordinary shares (“Sidhu Option Shares”). The vesting and exercisability of 1,000,000 Sidhu Option Shares accelerated as of July 24, 2024, with such Sidhu Option Shares remaining exercisable until their expiration date, and 250,000 Sidhu Option Shares will vest and become exercisable in equal tranches on each of the first, second and third anniversaries of April 8, 2024. Further, the Company determined that 700,000 Sidhu Option Shares would be fully exercisable until their expiration date. The separation agreement also contains a release of claims and incorporates customary obligations of confidentiality and non-disparagement. Dr. Sidhu continues to serve as a non-independent director on our Board. Kiran Nistala In addition to the Nistala Agreement’s three (3) month notice period described above, if Dr. Nistala’s employment is terminated by Zura UK without cause, Dr. Nistala would be entitled to a severance payment equal to three (3) months’ base salary, subject to signing a release and complying with his obligations under the Nistala Agreement. The Nistala Agreement also contains certain customary obligations, including confidentiality and cooperation. Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information From time to time, the Company grants stock options to its employees, including the named executive officers. Consistent with our annual compensation cycle, if stock options are to be granted, the Compensation Committee generally seeks to grant annual stock option awards in connection with their conducting and completing such annual review, which typically occurs in approximately the first quarter of each year. The Company has also granted new-hire option awards on or soon after a new hire’s employment start date. Additionally, non-employee directors receive grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of the Company’s shareholders, as further described under “Narrative to Director Compensation Table — 2024 Director Compensation Program” below. The Company does not seek to time the award